PCM
MLTX icon

Penserra Capital Management’s MoonLake Immunotherapeutics MLTX Stock Holding History

Penserra Capital Management’s Portfolio MLTX Stock Details MLTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-3,195
Closed -$16K – 1115
2022
Q2 		$16K Buy
+3,195
New +$20.1K ﹤0.01% 1153

Other funds holding MLTX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Penserra Capital Management's MLTX Position: Q3 2022 in Review

Penserra Capital Management sold out of MoonLake Immunotherapeutics (MLTX) in Q3 2022, closing a stake of 3,195 shares — an estimated $16K sold.

Penserra Capital Management first reported a position in MLTX in Q2 2022 and held it in 1 quarter. The position peaked at $16K in Q2 2022. 24 funds tracked by Wall St. Rank hold MLTX as of Q3 2022.

  • Penserra Capital Management reported no remaining MoonLake Immunotherapeutics position as of Q3 2022 after selling out during the quarter.
  • Penserra Capital Management sold 3,195 MoonLake Immunotherapeutics shares in Q3 2022, an estimated $16K.
  • Penserra Capital Management first reported a position in MoonLake Immunotherapeutics in Q2 2022 and held it in 1 quarter.
  • Penserra Capital Management's MoonLake Immunotherapeutics position peaked at $16K in Q2 2022.
  • 24 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q3 2022.

Based on Penserra Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.